AF
LAB icon

Amalgamated Financial’s Standard BioTools LAB Stock Holding History

Amalgamated Financial’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$34K Buy
+9,549
New +$33K ﹤0.01% 2578

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amalgamated Financial's LAB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Standard BioTools (LAB) in Q1 2022: 9,549 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #2578 among its holdings.

109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

  • Amalgamated Financial held 9,549 shares of Standard BioTools worth $34K as of Q1 2022.
  • Standard BioTools was a new Amalgamated Financial position in Q1 2022.
  • Standard BioTools made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2578 holding.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.